Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 3 studies | 29% ± 11% |
Insufficient scRNA-seq data for expression of YRDC at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 715.86 | 1445 / 1445 | 100% | 27.82 | 183 / 183 |
intestine | 100% | 606.37 | 966 / 966 | 100% | 37.27 | 527 / 527 |
ovary | 100% | 514.72 | 180 / 180 | 100% | 27.18 | 430 / 430 |
pancreas | 100% | 576.60 | 328 / 328 | 100% | 25.92 | 178 / 178 |
stomach | 100% | 600.76 | 359 / 359 | 100% | 31.84 | 286 / 286 |
lung | 100% | 704.03 | 578 / 578 | 100% | 35.78 | 1154 / 1155 |
prostate | 100% | 620.04 | 245 / 245 | 100% | 36.36 | 501 / 502 |
breast | 100% | 695.50 | 459 / 459 | 100% | 34.31 | 1115 / 1118 |
bladder | 100% | 636.81 | 21 / 21 | 100% | 38.53 | 502 / 504 |
skin | 100% | 1001.29 | 1809 / 1809 | 100% | 43.40 | 470 / 472 |
uterus | 100% | 511.39 | 170 / 170 | 99% | 33.66 | 456 / 459 |
brain | 99% | 532.12 | 2624 / 2642 | 100% | 34.03 | 705 / 705 |
liver | 100% | 572.27 | 226 / 226 | 99% | 19.65 | 403 / 406 |
thymus | 100% | 537.97 | 652 / 653 | 99% | 20.61 | 599 / 605 |
adrenal gland | 100% | 749.39 | 258 / 258 | 99% | 29.31 | 227 / 230 |
kidney | 100% | 618.47 | 89 / 89 | 98% | 20.11 | 886 / 901 |
adipose | 100% | 729.94 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 30.43 | 29 / 29 |
spleen | 100% | 694.51 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 28.24 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 25.26 | 1 / 1 |
blood vessel | 99% | 472.58 | 1328 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 24.24 | 78 / 80 |
heart | 97% | 323.66 | 833 / 861 | 0% | 0 | 0 / 0 |
muscle | 95% | 356.81 | 765 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 84% | 567.35 | 778 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0002949 | Biological process | tRNA threonylcarbamoyladenosine modification |
GO_0051051 | Biological process | negative regulation of transport |
GO_0006450 | Biological process | regulation of translational fidelity |
GO_0005886 | Cellular component | plasma membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0005739 | Cellular component | mitochondrion |
GO_0016779 | Molecular function | nucleotidyltransferase activity |
GO_0000049 | Molecular function | tRNA binding |
GO_0005515 | Molecular function | protein binding |
GO_0061710 | Molecular function | L-threonylcarbamoyladenylate synthase |
GO_0003725 | Molecular function | double-stranded RNA binding |
Gene name | YRDC |
Protein name | Threonylcarbamoyl-AMP synthase (EC 2.7.7.87) (Dopamine receptor-interacting protein 3) (Ischemia/reperfusion-inducible protein homolog) (hIRIP) |
Synonyms | DRIP3 IRIP |
Description | FUNCTION: Cytoplasmic and mitochondrial threonylcarbamoyl-AMP synthase required for the formation of a threonylcarbamoyl group on adenosine at position 37 (t(6)A37) in tRNAs that read codons beginning with adenine . Catalyzes the conversion of L-threonine, HCO(3)(-)/CO(2) and ATP to give threonylcarbamoyl-AMP (TC-AMP) as the acyladenylate intermediate, with the release of diphosphate . Participates in t(6)A37 formation in cytoplasmic and mitochondrial tRNAs . May regulate the activity of some transporters (By similarity). . |
Accessions | ENST00000373044.3 Q86U90 |